Literature DB >> 32802704

Current understanding of the effect of sodium-glucose co-transporter-2 inhibitors in Asian patients with diabetes mellitus.

Hirotaka Watada1,2,3,4.   

Abstract

Entities:  

Keywords:  Asian; Diabetes mellitus; Sodium–glucose cotransporter 2

Year:  2020        PMID： 32802704      PMCID： PMC7387392          DOI： 10.1007/s13340-020-00443-9

Source DB:  PubMed          Journal:  Diabetol Int        ISSN： 2190-1678


× No keyword cloud information.
  5 in total

1.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine
Journal:  N Engl J Med       Date:  2018-11-10       Impact factor: 91.245

2.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

3.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

4.  Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease　- Results From EMPA-REG OUTCOME®.

Authors:  Kohei Kaku; Jisoo Lee; Michaela Mattheus; Stefan Kaspers; Jyothis George; Hans-Juergen Woerle
Journal:  Circ J       Date:  2016-12-23       Impact factor: 2.993

5.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

Authors:  Christoph Wanner; Silvio E Inzucchi; John M Lachin; David Fitchett; Maximilian von Eynatten; Michaela Mattheus; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Bernard Zinman
Journal:  N Engl J Med       Date:  2016-06-14       Impact factor: 91.245
  5 in total
  2 in total

1.  Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).

Authors:  Kazuyuki Tobe; Hiroshi Maegawa; Ichiro Nakamura; Satoshi Uno
Journal:  Diabetol Int       Date:  2020-11-23

2.  Safety and Effectiveness of Ipragliflozin in Elderly Versus Non-elderly Japanese Patients with Type 2 Diabetes: Subgroup Analysis of STELLA-LONG TERM.

Authors:  Ichiro Nakamura; Hiroshi Maegawa; Kazuyuki Tobe; Satoshi Uno
Journal:  Diabetes Ther       Date:  2021-03-17       Impact factor: 2.945
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.